Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets

WSW, NY, June 22nd, 2026, FinanceWire

Nuvectis Pharma (NASDAQ: NVCT) opened the trading week with a transaction that transforms the small-cap precision-medicine developer into a multi-platform, late-stage biotech. Under a strategic in-licensing agreement with China's Haisco Pharmaceutical Group (SHE: 002653), Nuvectis is acquiring exclusive ex-China rights to two clinical-stage compounds for $40 million in upfront and near-term payments, up to $1.421 billion in milestones, and tiered royalties.

The deal extends Nuvectis's oncology platform - anchored by NXP900, an oral SRC/YES1 kinase inhibitor in Phase 1b - into a broader pipeline that now spans both oncology and immune complement-mediated disease. NXP900 remains central to the strategy: it includes a combination study with AstraZeneca's Tagrisso (osimertinib) in EGFR-mutated NSCLC, led by Dr. Zofia Piotrowska of Massachusetts General Hospital, an investigator on the registrational FLAURA program. Clinical inflection points from NXP900 are expected this summer.

NXP100 - a once-daily oral Complement Factor B inhibitor for paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy, and lupus nephritis - arrives with a strikingly clean dataset. In a randomized Phase 3 head-to-head trial in treatment-naïve PNH patients in China, 59.5% of NXP100 patients achieved hemoglobin ≥12 g/dL without transfusion versus 8.3% on Soliris (p<0.001), with superiority across every key secondary endpoint. In a separate Phase 3 in patients who had failed C5 inhibitor therapy, 52.8% met the same threshold. Two marketing applications are under review at China's NMPA. Composition-of-matter patent protection runs to 2043.

PNH has historically been an AstraZeneca franchise - Soliris and Ultomiris, the centerpiece of AZ's $39 billion acquisition of Alexion, once generated more than $6 billion combined. That injectable C5 business has shrunk to roughly $4.5 billion of today's $5-billion-plus PNH market under biosimilar and oral pressure. Novartis's twice-daily Factor B inhibitor Fabhalta - ramping from $81 million in Q1 2025 to $120 million in Q2 2025, with peak-sales projections of $5–10 billion - has shown where the category is heading. NXP100 enters that market once-daily, half the pill burden of Fabhalta, in a disease requiring lifelong therapy.

NXP200, an oral, brain-penetrant paradox-breaker BRAF inhibitor in Phase 1b in China, addresses a different but equally large opportunity. The first-generation BRAF class - Tafinlar, Braftovi, Zelboraf, Ojemda - generates roughly $4 billion annually but is structurally limited: it cannot inhibit Class II or Class III BRAF mutations, and in V600 disease it triggers paradoxical MAPK activation, driving resistance, secondary skin cancers, and the need for MEK-inhibitor combinations. Paradox-breakers are designed to address both.

In a completed dose-escalation study in heavily pretreated patients - including those previously progressed on BRAF/MEK combinations, single-agent NXP200 delivered a >40% response rate in low- and high-grade adult glioma including one complete response, plus durable responses in colorectal cancer, melanoma, NSCLC, and papillary thyroid carcinoma. A second-generation salt form has shown improved pharmacokinetics; patent protection runs to 2042. Recent M&A activity has highlighted strategic interest in the category: Servier acquired Day One Biopharmaceuticals for $2.5 billion in April 2026 for Ojemda, whose 2026 projected sales of $225–250 million represent only about 6% of the $4 billion BRAF market. NXP200's potential addressable population, spanning V600 and Class II/III BRAF-mutated solid tumors, is materially larger.

Haisco's year on the global stage has been remarkable. In January, it partnered with Frazier Life Sciences on AirNexis Therapeutics, a $200 million Series A NewCo worth up to $955 million in milestones. In April, AbbVie paid $30 million upfront with up to $715 million in milestones for two Haisco pain candidates. In May, Eli Lilly signed a five-program collaboration worth up to $3 billion. Nuvectis joins that roster: the company is led by Ron Bentsur, previously co-founder of UroGen Pharma (NASDAQ: URGN) and CEO of Keryx Biopharmaceuticals, with an executive team that has taken precision-medicine programs through FDA approval and commercial launch.

The strongest precedent for what Haisco-origin compounds can produce in Western hands is Alumis Inc. (NASDAQ: ALMS), which holds rights to envudeucitinib, the oral TYK2 inhibitor originated within Haisco-affiliated FronThera and acquired by Alumis in 2021. When Alumis reported positive Phase 3 data in plaque psoriasis on January 6, 2026, the company's market cap expanded from approximately $767 million pre-data to over $3 billion.

With NXP100's marketing applications under review in China, NXP900 inflection points this summer, and NXP200 readouts through 2026, the catalyst slate is rich. Existing cash is expected to fund operations into 2H 2027, with the Haisco transaction subject to financing conditions disclosed by the Company. The Haisco deal delivers exposure to two generational transitions in parallel - injectable C5 to oral Factor B in PNH, and first-generation V600 BRAFis to paradox-breakers in solid tumors - alongside the advancing NXP900 platform.

Read More Market Developments >>

What's Going On With Taiwan Semiconductor Stock Monday?

Ross Gerber Calls Waymo 'Way Safer And Better' Than Tesla's FSD, Questions Whether Elon Musk Can 'Catch Up'

Why Is Getty Images Stock Gaining Monday?

Recent News Developments from Nuvectis Pharma (NVCT):

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from Nuvectis Pharma, Inc. (the "Issuer") as part of a subscription to its coverage and awareness platform and services, which are provided on an ongoing subscription basis. The content above is informational purposes only and does not constitute financial or investment advice, nor is it objective given the above conflics disclosed. This article may contain forward-looking statements about the Issuer's products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer's public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.

Contact